• Publications
  • Influence
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
BACKGROUND Insufficient data are available from single cohort studies to allow estimation of the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral therapyExpand
  • 1,537
  • 59
  • PDF
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Summary Background Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, thisExpand
  • 983
  • 57
  • PDF
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
BACKGROUND Data from randomized trials are lacking on the benefits and risks of initiating antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) infection who have aExpand
  • 1,649
  • 48
  • PDF
Class of antiretroviral drugs and the risk of myocardial infarction.
BACKGROUND We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs accordingExpand
  • 1,017
  • 40
  • PDF
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
BACKGROUND An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liverExpand
  • 1,121
  • 33
  • PDF
Combination antiretroviral therapy and the risk of myocardial infarction.
BACKGROUND It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction. METHODS In this prospective observational study, weExpand
  • 1,252
  • 32
  • PDF
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs
BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events ofExpand
  • 581
  • 28
  • PDF
Meta-analysis: Principles and procedures
Meta-analysis is a statistical procedure that integrates the results of several independent studies considered to be “combinable.”1 Well conducted meta-analyses allow a more objective appraisal ofExpand
  • 1,806
  • 26
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease,Expand
  • 991
  • 26
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
Objectives:Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specificExpand
  • 342
  • 23
  • PDF